Bcl-2 is the best characterized inhibitor of apoptosis, although the molecular basis of this action is not fully understood. Using a protein interaction cloning procedure, we identi®ed a human gene designated as bis (mapped to chromosome 10q25) that encoded a novel Bcl-2-interacting protein. Bis protein showed no signi®cant homology with Bcl-2 family proteins and had no prominent functional motif. Co-immunoprecipitation analysis con®rmed that Bis interacted with Bcl-2 in vivo. DNA transfection experiments indicated that Bis itself exerted only weak anti-apoptotic activity, but was synergistic with Bcl-2 in preventing Bax-induced and Fas-mediated apoptosis. These results suggest that Bis is a novel modulator of cellular anti-apoptotic activity that functions through its interaction with Bcl-2.
Introduction
Apoptosis is a phylogenically conserved cellular suicide mechanism under tight genetic control, which plays an important role in various biological events including morphogenesis, tissue homeostasis and removal of harmful and unwanted cells (reviewed in Steller, 1995) . Dierent apoptotic signals induced by a variety of stimuli eventually converge into a common pathway driven by a family of cysteine proteases called caspases (reviewed in Martin and Green, 1995; Alnemri et al., 1996; Thornberry and Lazebnik, 1998) . This pathway is regulated by the Bcl-2 family of proteins (reviewed in Adams and Cory, 1998) which are the best characterized apoptosis regulators and consist of three distinct subfamilies; one includes anti-apoptotic Bcl-2, Bcl-x L and Bcl-w that share homology at four regions (BH1, 2, 3 and 4); the second includes pro-apoptotic Bax and Bak that share homology with Bcl-2 at BH1, 2 and 3; and the third includes pro-apoptotic Bik and Bid that only share homology with Bcl-2 at BH3. Antiapoptotic Bcl-2 and Bcl-x L proteins have been shown to prevent apoptosis by blocking the signal transduction pathway leading to activation of the caspase cascades (Chinnaiyan et al., 1996; Boulakia et al., 1996; Shimizu et al., 1996b; Armstrong et al., 1996) . This activity is apparently mediated via two distinct mechanisms: (1) prevention, by inhibiting the opening of VDAC (voltage-dependent anion channel on mitochondrial outer membrane) (Shimizu et al., 1999) , of the release of apoptogenic cytochrome c from the mitochondria (Kluck et al., 1997; Yang et al., 1997) , which activates caspase-9, one of the initiator caspases, in concert with a cytoplasmic protein Apaf-1, a mammalian homolog of C. elegans death protein Ced-4 (Li et al., 1997; Zou et al., 1997) , subsequently activating eector caspase-3, and (2) sequestration of procaspase-8 and -9 (Chinnaiyan et al., 1997) . A striking feature of Bcl-2 family of proteins is their ability to homodimerize and to heterodimerize, with heterodimerization between anti-apoptotic and proapoptotic members being proposed as a mechanism for regulating each partner's activity (Yin et al., 1994) , although some Bcl-2 family proteins such as Bcl-2 and Bax have been suggested to function independently (Knudson and Korsmeyer, 1997 ; for review, see Reed, 1998) . The only known activity of Bcl-2 family proteins is the formation of ion channels in synthetic lipid membranes (Minn et al., 1997; Schendel et al., 1997; Antonsson et al., 1997; Schlesinger et al., 1997) , although it is unclear whether this activity is linked to their regulation of apoptotic cell death.
A number of Bcl-2-binding proteins have been identi®ed, which do not belong to the family, and some of them have been shown to possess the ability to enhance anti-apoptotic activity in concert with Bcl-2. Such proteins include Bag-1 (Takayama et al., 1995) , Raf-1 (Wang et al., 1994) and SMN (Iwahashi et al., 1997) , the product of the spinal muscular atrophydetermining gene (Lefebvre et al., 1995) . Bag-1 was also shown to bind to and activate the Raf-1 kinase (Wang et al., 1996a) . Since Bag-1 interacts with cytoplasmic domain of HGF (hepatocyte growth factor) and PDGF (platelet-derived growth factor) upon induction of apoptosis (Bardelli et al., 1996) and Bcl-2 targets Raf-1 kinase to mitochondria (Wang et al., 1996b) , subcellular redistribution of these Bcl-2-binding proteins might be involved in the regulation of Bcl-2 activity. However, the precise molecular mechanisms underlying their enhancement of anti-apoptotic activity have not been determined.
To investigate the molecular basis and regulatory mechanisms of the anti-apoptotic activity of Bcl-2, we attempted to identify proteins that bind to Bcl-2 and modulate its activity. We detected a gene, termed bis, encoding a Bcl-2-interacting protein that was synergistic with Bcl-2 in preventing cell death.
Results

Molecular cloning of bis cDNA
To identify cDNAs encoding proteins which bind to Bcl-2, a human B cell cDNA library in the l phage expression vector (lgt11) was screened using recombinant human Bcl-2 protein expressed in a baculoviral expression system and a human Bcl-2-speci®c monoclonal antibody as described in Materials and methods. Two positive clones were initially isolated that had the same DNA sequence of 1377 base pairs (bp). Using this cDNA as a hybridization probe, further screening of the same cDNA library led to the identi®cation of a cDNA clone of 2550 bp containing a 1728 bp open reading frame. The original clone corresponded to the 3' portion of the larger cDNA.
The predicted amino acid sequence is shown in Figure 1 , revealing that this Bcl-2-binding protein, designated Bis (Bcl-2-interacting death suppressor), shows no homology with the Bcl-2 family of proteins and has no prominent functional motif except for a WW domain near the N terminus. The cDNA for the murine autholog of Bis was also obtained through identi®cation of several EST clones in databases and subsequent PCR using an 11-day mouse embryo cDNA library (Clontech) as the template. The primary sequence of murine Bis (mBis) is also shown in Figure  1 , indicating that its amino acid sequence shows 84% identity with that of human Bis.
Interaction of Bis with Bcl-2
To determine whether Bis binds to Bcl-2 in vitro, a GST-Bis (306 ± 575 aa) fusion protein immobilized on glutathione-agarose beads was incubated with lysates of cells expressing human Bcl-2. As shown in Figure  2a , Bcl-2 was speci®cally recovered on glutathione beads coated with GST-Bis but not on the beads coated with GST alone or plain beads, indicating that Bis bound to Bcl-2 in vitro.
To con®rm the interaction between Bis and Bcl-2 in vivo, Bis and Bcl-2 were co-expressed in Cos7 cells by transient transfection of the respective expression constructs. Immunoprecipitation of cell lysates using anti-Bis antibody and subsequent immunoblotting with anti-Bcl-2 antibody revealed that Bcl-2 was speci®cally co-immunoprecipitated with Bis ( Figure 2b ), indicating that Bis bound to Bcl-2 in mammalian cells. The same interaction between Bis and Bcl-2 was also observed in another mammalian cell line, HeLa D98 (data not shown), which was used for the functional analysis of Bis described below.
Tissue expression of bis gene
To determine the tissue-speci®c expression pro®le of bis, we carried out Northern blot analysis. As shown in Figure 3a , bis gene was expressed as a single mRNA species of *2.8 kb in a variety of adult human tissues, with high levels in skeletal muscle, heart and ovary. Expression of bis during mouse embryogenesis was also studied by Western blotting using an anti-human Bis antibody which cross-reacted with mBis, revealing that Bis was present in embryos as early as 10.5 days of gestation and that the amount of Bis increased towards birth (Figure 3b ).
Intracellular localization of Bis
To examine the intracellular localization of Bis, fractionation of HeLa cells was carried out as Figure 4a indicates that Bis was mainly present in the cytosol, with small amounts in the nuclear and light membrane fractions. The nuclear fraction treated with 0.5% NP40 to remove the nuclear envelope (Akao et al., 1994) did not contain Bis, indicating that Bis was not localized inside of the nucleus. Immuno¯uorescence microscopy con®rmed that Bis was a non-nuclear cytoplasmic protein, as shown in Figure 4b .
Determination of the Bis binding domain on Bcl-2
To determine the region of Bcl-2 required for interaction with Bis, we prepared a series of deletion mutants of human Bcl-2 and assessed their binding to Bis by co-expressing each mutant with Bis in Cos7 cells, followed by immunoprecipitation. Among the ten deletion mutants tested, that covered the entire region of Bcl-2, D141 ± 161 failed to associate with Bis and D121 ± 145 associated only weakly with Bis, while all other mutants retained their ability to bind to Bis ( Figure 5b and data not shown). The results suggested that part of BH1 domain of Bcl-2, which was deleted in D141 ± 161, was essential for the interaction between Bcl-2 and Bis. Furthermore, a substitution of Gly145 in the BH1 domain to Glu (G145E), which has been reported to abolish both the ability of Bcl-2 to prevent apoptotic cell death and to heterodimerize with Bax (Yin et al., 1994; Hengartner and Horvitz, 1994) , 
Synergism between Bis and Bcl-2 in preventing cell death
The interaction detected between Bis to Bcl-2 in vivo led us to examine whether Bis modulated the anti-apoptotic activity of Bcl-2. We used the microinjection procedure described previously (Iwahashi et al., 1997) , because this system allows manipulation of the level of expression of proteins derived from injected DNA in recipient cells with the same genetic background. Apoptosis of HeLa cells was induced by co-microinjection of mouse bax DNA. About 80% of cells showed apoptotic nuclear change by injection of mouse bax DNA alone (data not shown). Microinjection of a large amount of bis DNA conferred a low but signi®cant level of resistance to Baxinduced cell death (Figure 6a ), indicating that Bis had an anti-apoptotic activity, although it was weaker than that of Bcl-2. This seems not due to overexpression of nonspeci®c proteins, because b 2 -microglobulin DNA had no eect to prevent Bax-induced apoptosis (Iwahashi et al., 1997) . Co-injection of bis and bcl-2 DNA at relatively low concentrations, which alone did not confer signi®cant protection against Bax-induced cell death, resulted in enhancement of the protective eect (Figure 6b ). Virtually identical results were obtained when apoptosis was induced by treatment with an agonistic anti-Fas antibody (Figure 6c) . Thus, the synergistic anti-apoptotic activity of Bis and Bcl-2 seemed to apply to various stimuli.
We also assessed the activity of Bis by transient transfection. As shown in Figure 6d , HeLa cells expressing both Bis and Bcl-2 showed a higher survival rate than those expressing either of the two proteins when apoptosis was induced by anti-Fas antibody, consistent with the results of the microinjection experiments. A less prominent synergistic eect in the transient co-transfection experiment than in the microinjection experiment was probably due to diculty in achieving a minimal level of Bcl-2 expression with transient co-transfection.
Chromosomal localization of the human bis gene
The chromosomal location of the human bis gene was determined by¯uorescence in situ hybridization (FISH) as described in Materials and methods. A total of 43 metaphase cells were examined and a speci®c signal showing as twin spots on both sister chromatids was detected on the distal part of the long arm of chromosome 10 in seven metaphase cells. No speci®c signal was observed on any other regions of the chromosomes. By comparison with the DAPI banding pattern, the bis gene was assigned to the band 10q25 (Figure 7) . 
Discussion
We identi®ed a novel Bcl-2 binding protein, Bis, which showed synergism with Bcl-2 in preventing cell death. Based on its amino acid sequence, Bis showed no signi®cant homology with the Bcl-2 family of proteins and had no prominent functional motif. Several proteins, that do not belong to the Bcl-2 family, including Bag-1 (Takayama et al., 1995) , Raf-1 (Wang et al., 1994) and SMN (Iwahashi et al., 1997) , have been reported to interact with Bcl-2 and to enhance cellular anti-apoptotic activity in concert with Bcl-2. Since Bis shares no signi®cant sequence homology with these Bcl-2-interacting proteins, the mechanisms underlying the eect of Bis and the other proteins on Bcl-2 activity might be totally dierent.
Bis bound to Bcl-2 at the BH1 domain, which is also required for binding to Bax (Figure 5 ), so it can be hypothesized that Bis might compete with Bax in binding to Bcl-2 or that Bis might sequester Bax by direct binding, thereby preventing Bcl-2-Bax heterodimerization and resulting in enhancement of the antiapoptotic activity of Bcl-2. However, Bis did not interact with Bax, and the amount of Bax which bound to Bcl-2 was apparently unchanged in the presence or absence of Bis (data not shown), suggesting that the Bcl-2-Bax interaction was not aected by Bis.
Since Bis was mainly localized in the cytoplasm but not in the mitochondria, it seems like that Bis bound to non-mitochondrial Bcl-2. Small amounts of Bis were detected in the nuclear membrane fraction and light membrane fraction (primarily endoplasmic reticulum) where Bcl-2 is also localized (Hockenbery et al., 1990; Monaghan et al., 1992; Jacobson et al., 1993; Krajewski et al., 1993; Akao et al., 1994) . Bis might bind to Bcl-2 in those compartments, although the role of Bcl-2 in the endoplasmic reticulum and nuclear membrane, especially with respect to apoptotic cell death, has not yet been clari®ed. It is also conceivable that Bis associates with Bcl-2 just after it is released from the ribosomes, thereby participating in the import of Bcl-2 into the mitochondria or other compartments with the help of other cytosolic proteins, in a similar way to other mitochondrial proteins (reviewed in Neupert, 1997) .
Despite the predicted molecular weight of 65 kDa, Bis migrated as a protein doublet of *80 kDa when overexpressed in mammalian cells. Anti-Bis antibody also recognized an endogenous Bis protein in HeLa and Cos7 cells, which was slightly larger than Bis derived from transfected DNA. However, 5' and 3' RACE as well as PCR ampli®cation of cDNA from HeLa cells with several pairs of primers did not provide any evidence of a deletion or of alternative splicing (data not shown), suggesting that the slight dierence in molecular mass between endogenous Bis and transfected DNA-derived Bis might be due to posttranslational modi®cations.
The predicted amino acid sequence indicated that Bis had a WW domain located at residues 25 ± 52, near the N terminus. The WW domains have been reported in a variety of proteins, including oncoprotein Yesassociated protein (YAP), dystrophin, transcriptional factor FE65 and ubiquitin ligase Nedd4 (reviewed in Sudol, 1996) . Although the precise physiological role of the WW domain is not yet clear, it has been hypothesized that this domain may be a putative protein-binding site mediating protein-protein interactions, as suggested for several proteins, such as the epithelial sodium channel (ENaC) subunit, hematopoietic transcription factor p45/NF-E2 and RNA polymerase II (Schild et al., 1996; Gavva et al., 1997) . Since a part of Bis corresponding to the original clone (306 ± 575 aa), which was shown to bind to Bcl-2, lacked the WW domain, this domain does not seem to be directly involved in the interaction with Bcl-2. However, Bis could associate with another protein, through the WW domain and such an association might regulate the interaction of Bis with Bcl-2. Therefore, identi®cation of Bis-binding proteins, if present, might be useful to gain further insights in the role of Bis in cell death.
The bis gene was ubiquitously expressed in a variety of tissues in humans and mice with high levels in the heart and skeletal muscle cells, both of which are longlived but express Bcl-2 and Bcl-x L at low levels (Eguchi et al., 1992) . This suggests that Bis may enhance the very weak anti-apoptotic activity of Bcl-2 in heart and skeletal muscle, thus improving cell survival. Therefore, some of the heart diseases accompanied by death of cardiac myocytes as well as some degenerative diseases involving skeletal muscle might be associated with defects or reduced levels of Bis protein. The bis gene was localized to human chromosome 10q25, to which disease-responsible loci for two human disorders possibly caused by dysregulation of apoptosis have been mapped; insulin-dependent diabetes mellitus-17 (Verge et al., 1998) and split hand/foot malformation (Raas-Rothschild et al., 1996) .
While we were preparing this manuscript, a novel gene encoding silencer of death domain (SODD) was identi®ed (Jiang et al., 1999) . SODD associated with TNFR1 and DR3 to prevent spontaneous death signaling. An amino acid sequence homology search indicated that part of human Bis (422 ± 499 aa) showed 58% identity with the C-terminal 78 amino acid residues of SODD. At present, we are not sure whether Bis can associate with other death domain receptors. However, we have shown that Bis eectively enhances the Bcl-2 activity against Bax-induced cell death, which is independent of death receptors, probably excluding a major role of Bis in binding to death domain receptors.
Materials and methods
Screening of the cDNA library
A human B cell cDNA library in lgt11 (Clontech) was screened essentially as described elsewhere (Sambrook et al., 1989 ) using lysates of bcl-2-baculovirus-infected Sf9 cells which were prepared as described (Reed et al., 1992) . Brie¯y, the cDNA library was plated on E. coli Y1090 cells at 378C and then incubated at 428C for 3 h. Phage plates were then overlaid with nitrocellulose ®lters soaked in 10 mM isopropylb-D thiogalactoside (IPTG) for 3 h at 378C. After washing with TBS buer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl) containing 0.05% Tween 20, the ®lters were treated twice with 6 M guanidine-HCl in HBB buer (20 mM HEPES, pH 7.5, 5 mM MgCl 2 , 1 mM KCl, 5 mM DTT) for 10 min each and then with 3 M guanidine-HCl in HBB buer three times for 5 min each. After blocking with 2% skim milk, the ®lters were incubated overnight at 48C with 2 ml of a cleared lysate prepared from 2610 7 bcl-2-baculovirus-infected Sf9 cells in RIPA buer (1% NP40, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 10 mM APMSF, 0.1 u/ml aprotinin, 5 mg/ ml leupeptin) diluted with 20 ml of TBS buer. For the detection of positive clones producing Bcl-2-interacting proteins, the ®lters were incubated with an anti-human Bcl-2 monoclonal antibody (clone 100) and then with alkaline phosphatase-conjugated goat anti-mouse IgG antibody. Alkaline phosphatase activity was visualized with NBT/ BCIP (Promega) as the substrate. DNA inserts from positive clones were subcloned into the pBluescript SK vector (Clontech). Using this original clone as a hybridization probe labeled with 32 P, the same library was further screened to obtain additional clones as described elsewhere (Sambrook et al., 1989) . After subcloning and sequencing of the additional clones, the bis cDNA sequence was determined.
Antibodies
The anti-human Bcl-2 monoclonal antibody (clone 100) has been described previously (Pezzella et al., 1990) . Agonistic anti-human Fas antibody (CH11) and rhoadamine isothiocyanate (RITC)-conjugated goat anti-rabbit IgG were purchased from MBL (Japan). A polyclonal rabbit antihuman Bis antibody that cross-reacted with murine Bis and green monkey Bis was raised against a GST-Bis (306 ± 575 aa) fusion protein.
In vitro binding assay
The in vitro binding assay of Bcl-2 and Bis was performed using a glutathione S-transferase (GST)-Bis fusion protein and Bcl-2 expressed in mouse cells. To prepare the GST-Bis fusion protein, a human bis cDNA (1196 ± 2550 bp; 306 ± 575 aa) was subcloned into EcoRI site of the pGEX1 vector. E. coli strain AR68 transformed with pGEX1 or pGEX1-bis was treated with 1 mM IPTG for 2 h at 378C, and then sonicated on ice in buer (50 mM Tris-HCl, pH 7.5, 25% saccharose, 0.5% NP40, 5 mM MgCl 2 ). After centrifugation, the supernatant was mixed with glutathione-agarose beads (Pharmacia), for 1 h at 48C and washed three times with buer (20 mM Tris-HCl, pH 7.5, 2 mM MgCl 2 , 1 mM DTT). The beads were then incubated for 2 h at 48C with 200 ml of the lysates from 10 7 MT2-Bcl-2 cells (a murine T cell lineoverexpressing human Bcl-2) in RIPA buer. After washing three times with RIPA buer, the proteins bound on the beads were eluted with SDS sample buer and subjected to SDS ± PAGE followed by Western blot analysis with the antiBcl-2 monoclonal antibody.
Plasmid construction
Human bis (hbis), human bcl-2 (hbcl-2), human bax (hbax) and mouse bax (mbax) cDNAs were subcloned into the pUC-CAGGS (pCAGGS) expression plasmid containing a b-actin promotor and CMV enhancer (Niwa et al., 1991) . DNAs for deletion mutants of Bcl-2 were generated by PCR and cloned into the pCAGGS vector. The DNA sequences were con®rmed.
Immunoprecipitation and Western blotting
Cos7 cells and HeLa cells, grown in DMEM with 10% fetal bovine serum (FBS) and RPMI 1640 with 10% FBS, respectively, were transfected using lipofectAMINE (Gibco BRL) with various DNA combinations in pCAGGS. Cells were incubated for 48 h in the medium and harvested for immunoprecipitation. Cells were lysed by sonication in NP40 isotonic lysis buer (Oltavi et al., 1993) and precleared with 5% (v/v) protein-G-Sepharose (Pharmacia) for 1 h. Lysates were incubated with anti-Bis antibody or normal rabbit serum for 2 h at 48C with constant rotation, and then with 5% (v/v) protein G-Sepharose for an additional 1 h. Cell lysates and immunoprecipitates were separated by 12.5% SDS ± PAGE and immunoblotted with the indicated antibodies using an ECL system (Amersham).
Subcellular fractionation
Subcellular fractionation of HeLa cells was carried out as described (Akao et al., 1994) . Brie¯y, cells were washed with phosphate-buered saline (PBS) and suspended in hypotonic solution [10 mM 4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid, 10 mM MgCl 2 , 42 mM KCl] for 5 min on ice. Cells were passed through 30 gauge needle and centrifuged at 600 g for 10 min to collect crude nuclei. The supernatant was centrifuged at 10 000 g for 10 min. The pellet was recovered as heavy membrane fraction. The supernatant was further centrifuged at 100 000 g for 90 min. The pellet and supernatant were used as light membrane and cytoplasmic fractions, respectively. Pelleted fractions were dissolved in 26PBS, 1% NP40, 0.5% deoxycholate and 0.1% sodium dodecyl sulfate. NP40 treated nuclei were prepared by lysing cells suspended in the hypotonic solution using 0.5% NP40. The integrity of the nuclei was checked under a light microscope.
Immuno¯uorescence microscopy
HeLa cells plated on glass coverslips were ®xed in 4% formaldehyde in PBS for 10 min, washed with PBS three times, and permeabilized with methanol for 10 min. After blocking in 5% skim milk for 30 min, cells were incubated with anti-Bis antibody at 48C overnight. After washing with PBS, cells were treated with RITC-conjugated goat antirabbit IgG for 15 min before observation under a fluorescence microscope (Olympus, Japan).
Analysis of cell death
Microinjection and subsequent analysis of cell death were carried out as described elsewhere Iwahashi et al., 1997) . Brie¯y, HeLa cells were seeded on glass coverslips with RPMI 1640 containing 10% FBS, and DNA(s) in PBS were microinjected into the nucleus using a Leica microinjection system. Cell death was induced by comicroinjecting a mouse Bax expression plasmid, pCAGGSmbax (Iwahashi et al., 1997) at 20 ng/ml followed incubation for 3 h, or by treatment of DNA-injected cells with 1 mg/ml of the agonistic anti-Fas mAb (CH11) for 4 h. Total DNA concentrations were adjusted to 200 ng/ml with vector DNA (pCAGGS). RITC-labeled BSA (5.8 mg/ml) (Tachibana et al., 1994) was always co-injected to identify the injected cells. After the indicated periods, cells were ®xed with 10% formaldehyde solution for 20 min, stained with Hoechst 33342 (Calbiochem) for 5 min, and analysed under ā uorescence microscope (Olympus BX-50, Japan) with excitation at 480 nm for RITC and at 360 nm for Hoechst 33342. Apoptotic cells were identi®ed on the basis of condensed chromatin and/or fragmented nuclei stained with Hoechst 33342 (Shimizu et al., 1996a) .
For the transient transfection cell death assay, HeLa cells in 6-well plates were transfected with expression plasmids together with pEGFP-N1 (Clontech), a reporter plasmid encoding a green¯uorescence protein (GFP). Eight hours after transfection, apoptosis was induced by treatment for 3 h with agonistic anti-Fas mAb (CH11). Apoptotic cells (round cells with membrane blebbing) were detected among GFPpositive cells by¯uorescence microscopy and phase contrast microscopy.
In situ hybridization
To determine the chromosomal localization of the human bis gene, FISH was performed as described previously (Inazawa et al., 1993) . A 2.0 kb bis cDNA was labeled with biotin-16-dUTP (Boehringer) by nick translation, and hybridized to the denatured chromosomes at a ®nal concentration of 25 ng/ml in 50% formamide, 10% dextran sulfate, 26SSC, 2 mg/ml of salmon sperm DNA, and 2 mg/ml E. coli tRNA. Metaphase chromosomes were prepared by the thymidine synchronization, bromodeoxy uridine release technique for delineation of the replication G-band. The hybridization signals were ampli®ed with¯uorescein isothiocyanate-avidin and biotinylated anti-avidin D. Metaphase cells were counterstained with propidium iodide, and the slides were examined through a Nikon epi¯uorescent microscope (ECLIPSE 800).
Note added in proof
During the preparation of our manuscript, the sequence of human Bag-3 was released in the GenBank database, that is identical to that of human Bis.
